Kymera Therapeutics, Inc. beat EPS estimates 67% of the time across 3 reported quarters (2 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-0.64 | $-0.62 | +3.1% | Beat |
| Q12026 FY2026 | $-0.89 | $-0.71 | +20.2% | Beat |
| Q42025 FY2025 | $-0.77 | $-0.97 | -26.0% | Miss |
Back to KYMR overview · KYMR holders · KYMR KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.